Glycemic Management

SAN DIEGO — Adults with obesity who received the highest dose of a once-weekly injection of retatrutide lost an average of 24.2% of their body weight at 48 weeks compared with placebo, data from a phase 2 study show.

SAN DIEGO — Oral semaglutide 50 mg induces more than 15% weight loss in adults with obesity at 68 weeks and can reduce HbA1c by 2 percentage points at 52 weeks for those with type 2 diabetes, according to data from two phase 3 trials.

SAN DIEGO — Early time-restricted eating may confer more cardiometabolic benefits for adults than late time-restricted eating, but a later eating window may result in better adherence, according to two speakers.

People with type 2 diabetes who spend more time in glycemic range have lower risks for major adverse cardiovascular events, severe hypoglycemia and microvascular events, according to a post hoc analysis of the DEVOTE trial.

The FDA has approved two forms of empagliflozin as an adjunct to diet and exercise to improve glycemic control in children with type 2 diabetes, according to a press release.

CHICAGO — A small cohort of adults with obesity and prediabetes had lower glucose elevations and spent less time above range when they ate most of their calories before 1 p.m. compared with a more typical, later eating pattern.

The FDA granted clearance for use of a standalone reader to display real-time glucose levels with an integrated continuous glucose monitoring system, according to a press release.